1887

Abstract

Since its discovery in 1965, our understanding of the hepatitis B virus (HBV) replication cycle and host immune responses has increased markedly. In contrast, our knowledge of the molecular biology of hepatitis delta virus (HDV), which is associated with more severe liver disease, is less well understood. Despite the progress made, critical gaps remain in our knowledge of HBV and HDV replication and the mechanisms underlying viral persistence and evasion of host immunity. The International HBV Meeting is the leading annual scientific meeting for presenting the latest advances in HBV and HDV molecular virology, immunology, and epidemiology. In 2023, the annual scientific meeting was held in Kobe, Japan and this review summarises some of the advances presented at the Meeting and lists gaps in our knowledge that may facilitate the development of new therapies.

Funding
This study was supported by the:
  • Japan Agency for Medical Research and Development (Award JP24fk0310518)
    • Principle Award Recipient: YasuhitoTanaka
  • Ministry of Education (Award MOE 113L901401)
    • Principle Award Recipient: Shiou-HweiYeh
  • National Science and Technology Council (Award NSTC 112-2321-B-002-013-, NSTC 112-2326-B-002-011)
    • Principle Award Recipient: Shiou-HweiYeh
  • National Institute of Health (Award (R01AI110762, R01AI134818, R01AI150255, R21AI179929, R56AI179574, P30CA047904, P30DK120531))
    • Principle Award Recipient: HaitaoGuo
  • Japan Science and Technology Agency (JST) MIRAI program (Award JPMJMI22G1)
    • Principle Award Recipient: KoichiWatashi
  • Japan Society for the Promotion of Science (JSPS) KAKENHI (Award JP20H03499)
    • Principle Award Recipient: KoichiWatashi
  • Japan Agency for Medical Research and Development (AMED) (Award JP24fk0310504)
    • Principle Award Recipient: KoichiWatashi
  • National Health and Medical Research Council (Award 2018787)
    • Principle Award Recipient: PeterA Revill
  • National Institutes of Health (Award R01 AI138797, R01 AI153236, R01 AI146917, R01 AI168048 and R01 AI107301, U19A171401)
    • Principle Award Recipient: AlexanderPloss
  • Japan Agency for Medical Research and Development (Award JP23fk0310517)
    • Principle Award Recipient: MasamichiMuramatsu
  • Chinese Academy of Medical Sciences Innovation Fund for Medical Science, (Award 2018-I2M-2-002)
    • Principle Award Recipient: JaneA McKeating
  • Wellcome Discovery Award (Award 225198/Z/22/Z)
    • Principle Award Recipient: JaneA McKeating
  • Wellcome Investigator Award (Award 200838/Z/16/Z)
    • Principle Award Recipient: JaneA McKeating
  • Italian Ministry for University and Research Grants (Award PE00000007 (INF-ACT) and PRIN 2022FMESXL)
    • Principle Award Recipient: MatteoIannacone
  • Italian Association for Cancer Research (Award 19891 and 22737)
    • Principle Award Recipient: MatteoIannacone
  • ERC Consolidator Grant (Award 957502 and 101138728)
    • Principle Award Recipient: MatteoIannacone
  • European Research Council (ERC) Consolidator Grant (Award 725038)
    • Principle Award Recipient: MatteoIannacone
  • Italian Ministry for University and Research Grants (Award PE00000007)
    • Principle Award Recipient: ValeriaFumagalli
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001978
2024-05-16
2024-06-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/105/5/jgv001978.html?itemId=/content/journal/jgv/10.1099/jgv.0.001978&mimeType=html&fmt=ahah

References

  1. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol 2007; 13:48–64 [View Article] [PubMed]
    [Google Scholar]
  2. Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol 2016; 64:S4–S16 [View Article] [PubMed]
    [Google Scholar]
  3. World Health Organisation Global hepatitis report; 2017 https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
  4. Polaris Observatory C. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018; 3:383–403
    [Google Scholar]
  5. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–249 [View Article] [PubMed]
    [Google Scholar]
  6. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016; 388:1081–1088 [View Article] [PubMed]
    [Google Scholar]
  7. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 93:230–239 [View Article] [PubMed]
    [Google Scholar]
  8. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104–1108 [View Article] [PubMed]
    [Google Scholar]
  9. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750–1758 [View Article] [PubMed]
    [Google Scholar]
  10. Seetharam A, Perrillo R, Gish R. Immunosuppression in patients with chronic hepatitis B. Curr Hepatol Rep 2014; 13:235–244 [View Article] [PubMed]
    [Google Scholar]
  11. Lim SG, Baumert TF, Boni C, Gane E, Levrero M et al. The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol 2023; 20:238–253 [View Article] [PubMed]
    [Google Scholar]
  12. Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 2019; 4:545–558 [View Article] [PubMed]
    [Google Scholar]
  13. Flores R, Owens RA, Taylor J. Pathogenesis by subviral agents: viroids and hepatitis delta virus. Curr Opin Virol 2016; 17:87–94 [View Article] [PubMed]
    [Google Scholar]
  14. Taylor J, Pelchat M. Origin of hepatitis delta virus. Future Microbiol 2010; 5:393–402 [View Article] [PubMed]
    [Google Scholar]
  15. Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol 2020; 73:523–532 [View Article] [PubMed]
    [Google Scholar]
  16. Thiyagarajah K, Basic M, Hildt E. Cellular factors involved in the hepatitis D virus life cycle. Viruses 2023; 15:1687 [View Article] [PubMed]
    [Google Scholar]
  17. McNaughton AL, D’Arienzo V, Ansari MA, Lumley SF, Littlejohn M et al. Insights from deep sequencing of the HBV genome-unique, tiny, and misunderstood. Gastroenterology 2019; 156:384–399 [View Article] [PubMed]
    [Google Scholar]
  18. Revill PA, Tu T, Netter HJ, Yuen LKW, Locarnini SA et al. The evolution and clinical impact of hepatitis B virus genome diversity. Nat Rev Gastroenterol Hepatol 2020; 17:618–634 [View Article] [PubMed]
    [Google Scholar]
  19. Wagner J, Yuen L, Littlejohn M, Sozzi V, Jackson K et al. Analysis of hepatitis B virus haplotype diversity detects striking sequence conservation across genotypes and chronic disease phase. Hepatology 2021; 73:1652–1670 [View Article] [PubMed]
    [Google Scholar]
  20. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46:254–265 [View Article] [PubMed]
    [Google Scholar]
  21. Delphin M, Mohammed KS, Downs LO, Lumley SF, Waddilove E et al. Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection. Lancet Gastroenterol Hepatol 2024; 9:383–392 [View Article] [PubMed]
    [Google Scholar]
  22. Zheng Y, Wang M, Yin J, Duan Y, Wu C et al. Hepatitis B virus RNAs co-opt ELAVL1 for stabilization and CRM1-dependent nuclear export. PLoS Pathog 2024; 20:e1011999 [View Article] [PubMed]
    [Google Scholar]
  23. Mendenhall MA, Hong X, Hu J. Hepatitis B virus capsid: the core in productive entry and covalently closed circular DNA formation. Viruses 2023; 15:642 [View Article] [PubMed]
    [Google Scholar]
  24. Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an In Vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles. J Virol 2018; 92:e02007-17 [View Article] [PubMed]
    [Google Scholar]
  25. Kojima R, Nakamoto S, Kogure T, Ma Y, Ogawa K et al. Re-analysis of hepatitis B virus integration sites reveals potential new loci associated with oncogenesis in hepatocellular carcinoma. World J Virol 2023; 12:209–220 [View Article] [PubMed]
    [Google Scholar]
  26. Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2021; 74:283–292 [View Article] [PubMed]
    [Google Scholar]
  27. Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut 2018; 67:2045–2053 [View Article] [PubMed]
    [Google Scholar]
  28. Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol 2022; 22:19–32 [View Article] [PubMed]
    [Google Scholar]
  29. Kosinska AD, Festag J, Mück-Häusl M, Festag MM, Asen T et al. Immunogenicity and antiviral response of therapeutic hepatitis B vaccination in a mouse model of HBeAg-negative, persistent HBV infection. Vaccines 2021; 9:841 [View Article] [PubMed]
    [Google Scholar]
  30. Pearlman B. Hepatitis delta infection: a clinical review. Semin Liver Dis 2023; 43:293–304 [View Article] [PubMed]
    [Google Scholar]
  31. Bassit L, Amblard F, Patel D, Biteau N, Chen Z et al. The premise of capsid assembly modulators towards eliminating HBV persistence. Expert Opin Drug Discov 2023; 18:1031–1041 [View Article] [PubMed]
    [Google Scholar]
  32. Amblard F, Boucle S, Bassit L, Cox B, Sari O et al. Novel hepatitis B virus capsid assembly modulator induces potent antiviral responses In Vitro and in humanized mice. Antimicrob Agents Chemother 2020; 64:e01701-19 [View Article] [PubMed]
    [Google Scholar]
  33. Pérez-Vargas J, Pereira de Oliveira R, Jacquet S, Pontier D, Cosset F-L et al. HDV-Like viruses. Viruses 2021; 13:1207 [View Article] [PubMed]
    [Google Scholar]
  34. Hesterman MC, Furrer SV, Fallon BS, Weller ML. Analysis of hepatitis D virus in minor salivary gland of Sjögren’s disease. J Dent Res 2023; 102:1272–1279 [View Article] [PubMed]
    [Google Scholar]
  35. Rizzetto M. Chronic hepatitis D; at a standstill?. Dig Dis 2016; 34:303–307 [View Article] [PubMed]
    [Google Scholar]
  36. Blumberg BS, Alter HJ, Visnich S. A "New" antigen in Leukemia Sera. JAMA 1965; 191:541–546 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001978
Loading
/content/journal/jgv/10.1099/jgv.0.001978
Loading

Data & Media loading...

Supplements

Supplementary material 1

EXCEL
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error